Introduction The pharmaceutical industry is at a critical inflection point in 2025, with research and development (R&D) continuing to grow despite global economic pressures and shifting regulatory landscapes. As thousands…
Introduction The biopharmaceutical industry landscape is constantly evolving, and in-licensing and partnering deals are vital corporate strategies for driving innovation, devising new products, and gaining a competitive edge in the…
Effectively Integrating Competitor Analysis into New Product Planning to Maximize Biopharma Asset Value In the biopharmaceutical industry, the predominant focus of New Product Planning (NPP) initiatives often revolves around individual…
Finessing Pharma and Biotech Product Strategies in the Post-Inflation Reduction Act Era The recent passage of the Inflation Reduction Act (IRA) introduces sweeping changes for the biopharmaceutical industry through new…
A Value-Driven Commercialization Strategy for Pharmaceutical Assets An optimal commercialization strategy for pharmaceutical and biotechnology companies is vital for the value maximization of the company. Early-stage, as well as developed…